MXPA98002791A - Composiciones liposomales y metodos para usarlas. - Google Patents

Composiciones liposomales y metodos para usarlas.

Info

Publication number
MXPA98002791A
MXPA98002791A MXPA98002791A MX9802791A MXPA98002791A MX PA98002791 A MXPA98002791 A MX PA98002791A MX PA98002791 A MXPA98002791 A MX PA98002791A MX 9802791 A MX9802791 A MX 9802791A MX PA98002791 A MXPA98002791 A MX PA98002791A
Authority
MX
Mexico
Prior art keywords
liver
fenestrations
atherogenic lipoprotein
liposomes
cholesterol
Prior art date
Application number
MXPA98002791A
Other languages
English (en)
Inventor
Kevin Jon Williams
Original Assignee
Esperion Luv Dev Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Luv Dev Inc filed Critical Esperion Luv Dev Inc
Publication of MXPA98002791A publication Critical patent/MXPA98002791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1601—Control or regulation
    • A61M1/1619—Sampled collection of used dialysate, i.e. obviating the need for recovery of whole dialysate quantity for post-dialysis analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3424—Substitution fluid path
    • A61M1/3427—Substitution fluid path back through the membrane, e.g. by inverted trans-membrane pressure [TMP]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/342—Adding solutions to the blood, e.g. substitution solutions
    • A61M1/3424—Substitution fluid path
    • A61M1/3437—Substitution fluid path downstream of the filter, e.g. post-dilution with filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/60—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving cholesterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

La presente invencion proporciona una composicion liposomal, metodo para usar la composicion liposomal, y dispositivos y modos de operacion de los dispositivos y de las composiciones, y equipos relacionados a los mismos. La invencion se proporciona para el transporte inverso de colesterol desde tejidos perifericos al higado en un mamifero de sangre caliente mientras controla las concentraciones de lipoproteina aterogenica del plasma, que incluye las concentraciones de LDL. El metodo y modo de operacion de los dispositivos incluye la etapa de administrar una cantidad efectiva de multiplicidad de aceptores comprendidos de fosfolipidos substancialmente libres de esterol. El metodo opcionalmente incluye la etapa de ensayar periodicamente las concentraciones de lipoproteinas aterogenicas con un ensayo durante el periodo del tratamiento para evaluar las concentraciones de lipoproteina aterogenica y obtener un perfil de la lipoproteina aterogenica, y ajustar la administracion en respuesta al perfil. Los liposomas grandes son dimensionados mas grandes que las fenestraciones de una capa endotelial que alinea las sinusoidales hepaticas en el higado de tal forma que los liposomas son muy grandes para penetrar facilmente las fenestraciones de una variante. Las cantidades terapeuticamente efectivas estan el rango de aproximadamente 10 mg a aproximadamente 1600 mg de fosfolipidos por kg de peso corporal por dosis. Se proporciona tambien una composicion farmaceutica y equipo relacionado para movilizar colesterol periferico y esfingomielina que entran al higado de un individuo que consiste esencialmente de liposomas de un tamano y conformacion mayor que las fenestraciones de una capa endotelial que alinea las sinusoidales hepaticas en el higado. Se proporciona tambien la invencion para controlar los genes y otros compuestos relacionados con el colesterol.
MXPA98002791A 1995-10-11 1996-10-11 Composiciones liposomales y metodos para usarlas. MXPA98002791A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US509095P 1995-10-11 1995-10-11
PCT/US1996/016388 WO1997013501A1 (en) 1995-10-11 1996-10-11 Liposomal compositions and methods of using them
US08/728,705 US5843474A (en) 1995-10-11 1996-10-11 Method of dialysis treatment, and dialysis apparatus related thereto

Publications (1)

Publication Number Publication Date
MXPA98002791A true MXPA98002791A (es) 2004-09-07

Family

ID=21714125

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA98002791A MXPA98002791A (es) 1995-10-11 1996-10-11 Composiciones liposomales y metodos para usarlas.

Country Status (9)

Country Link
US (8) US5858400A (es)
EP (1) EP0863748A4 (es)
JP (1) JP2002515856A (es)
CN (1) CN1119145C (es)
AU (1) AU759964B2 (es)
CA (1) CA2231547A1 (es)
EA (1) EA199800279A1 (es)
MX (1) MXPA98002791A (es)
WO (1) WO1997013501A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5746223A (en) 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US6773719B2 (en) * 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US6312719B1 (en) 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5858400A (en) * 1995-10-11 1999-01-12 Talaria Therapeutics, Inc. Method of suppressing a rise in LDL concentrations after administration of an agent having small acceptors
AU1753497A (en) * 1996-01-26 1997-08-20 California Institute Of Technology Sol-gel encapsulation of lipid vesicles, lipid membranes and proteins
US6569147B1 (en) * 1996-07-26 2003-05-27 Kensey Nash Corporation Systems and methods of use for delivering beneficial agents for revascularizing stenotic bypass grafts and other occluded blood vessels and for other purposes
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6214887B1 (en) 1997-03-24 2001-04-10 Quatro Scientific, Inc. Vascular remodeling agent
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
AU780658B2 (en) * 1999-03-26 2005-04-07 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
US20020132223A1 (en) * 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (en) * 1999-03-26 2006-06-21 City of Hope Screening for FXR receptor modulators
WO2000069412A1 (en) * 1999-05-14 2000-11-23 Esperion Luv Development, Inc. Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto
US6586189B2 (en) 1999-06-18 2003-07-01 City Of Hope Screening method for PPAR-γ ligands
US6548739B2 (en) * 1999-06-18 2003-04-15 City Of Hope Method for activating peroxisome proliferator activated receptor-γ
AU2001252944A1 (en) * 2000-03-24 2001-10-08 City Of Hope Methods of modulating drug clearance mechanisms by altering SXR activity
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
WO2004014359A1 (en) * 2001-03-16 2004-02-19 Thomas Jefferson University Regulation of apob in treatment and drug screening for cardiovascular and metabolic disorders or syndromes
DE10117043A1 (de) * 2001-04-05 2002-11-07 Gerhard Puetz Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen
NL1018354C2 (nl) * 2001-06-21 2002-12-30 Kokbing Lo Inrichting voor het toedienen van een behandelingsvloeistof en het gebruik van een dergelijke inrichting voor het locaal in een orgaan bestrijden van kanker.
WO2003013955A2 (en) * 2001-08-06 2003-02-20 Vector Controls, Inc Integral reversing and trim deflector and control mechanism
YU26304A (sh) * 2001-09-28 2006-08-17 Esperion Therapeutics Inc. Postupci i uređaji za ekstruziju vezikula pod visokim pritiskom
IL161110A0 (en) * 2001-09-28 2004-08-31 Esperion Therapeutics Inc Prevention and treatment of restenosis by local admistration of drug
EP2277887A3 (en) 2001-10-19 2011-02-16 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US20030077310A1 (en) 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US20050058698A1 (en) * 2002-01-21 2005-03-17 Nolan Yvonne Mairead Pharmaceutically acceptable phosphate-glycerol carrying bodies and uses relating to Parkinson's Disease
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
BR0310100A (pt) * 2002-05-17 2007-04-27 Esperion Therapeutics Inc métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
US7153286B2 (en) 2002-05-24 2006-12-26 Baxter International Inc. Automated dialysis system
US7175606B2 (en) 2002-05-24 2007-02-13 Baxter International Inc. Disposable medical fluid unit having rigid frame
US7238164B2 (en) 2002-07-19 2007-07-03 Baxter International Inc. Systems, methods and apparatuses for pumping cassette-based therapies
AU2003266165A1 (en) * 2002-09-13 2004-04-30 Hossein Dovlatabadi Methods and compositons for the use of d-malic acid to decrease serum triglyceride, cholesterol, and lipoprotein levels
WO2004073684A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US8029454B2 (en) 2003-11-05 2011-10-04 Baxter International Inc. High convection home hemodialysis/hemofiltration and sorbent system
US7959659B2 (en) * 2004-01-02 2011-06-14 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US8926958B2 (en) * 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
CA2574013A1 (en) * 2004-07-14 2006-01-19 By-Pass, Inc. Material delivery system
DE102005045152A1 (de) * 2005-09-21 2007-03-22 Stremmel, Wolfgang, Prof. Dr. Verwendung von therapeutisch wirksamen Lipiden nebst Verfahren zur Herstellung von Organ-/Gewebe-spezifischen therapeutisch wirksamen Lipiden
KR100752414B1 (ko) 2006-09-15 2007-08-28 주식회사 뉴하트바이오 Ｐｓａｆ 인공 간 시스템
US20080140001A1 (en) * 2006-12-12 2008-06-12 By-Pass Inc. Fluid Delivery Apparatus And Methods
US20080181928A1 (en) * 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
CN101244089B (zh) 2007-02-16 2013-09-25 信谊药厂 嗜酸乳杆菌/粪肠球菌培养基、制剂及其工艺
CN101244090B (zh) 2007-02-16 2011-12-28 信谊药厂 长型双岐杆菌培养基、制剂及其工艺
US8512553B2 (en) 2007-07-05 2013-08-20 Baxter International Inc. Extracorporeal dialysis ready peritoneal dialysis machine
US8717412B2 (en) * 2007-07-18 2014-05-06 Samsung Electronics Co., Ltd. Panoramic image production
US8068693B2 (en) * 2007-07-18 2011-11-29 Samsung Electronics Co., Ltd. Method for constructing a composite image
US20090226501A1 (en) * 2007-12-07 2009-09-10 Boston Scientific Scimed, Inc. Drug coated stent with endosome-disrupting conjugate
DE102008010691A1 (de) * 2008-02-22 2009-08-27 Universität Rostock Bioäquivalenzdialyse
US8882700B2 (en) 2008-05-02 2014-11-11 Baxter International Inc. Smart patient transfer set for peritoneal dialysis
US9348975B2 (en) 2008-05-02 2016-05-24 Baxter International Inc. Optimizing therapy outcomes for peritoneal dialysis
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
US8062513B2 (en) 2008-07-09 2011-11-22 Baxter International Inc. Dialysis system and machine having therapy prescription recall
US9514283B2 (en) 2008-07-09 2016-12-06 Baxter International Inc. Dialysis system having inventory management including online dextrose mixing
US9445975B2 (en) 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
US8377012B2 (en) 2009-01-30 2013-02-19 Baxter International Inc. Transfer sets for therapy optimization
US8282829B2 (en) 2009-05-20 2012-10-09 Baxter International Inc. System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology
US9020827B2 (en) 2009-10-16 2015-04-28 Baxter International Inc. Peritoneal dialysis optimized using a patient hand-held scanning device
CN102858153A (zh) * 2010-03-12 2013-01-02 加利福尼亚大学董事会 纳米粒子稳定化的脂质体的触发活性物释放
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
US9440017B2 (en) 2013-03-14 2016-09-13 Baxter International Inc. System and method for performing alternative and sequential blood and peritoneal dialysis modalities
WO2018045015A1 (en) * 2016-09-01 2018-03-08 Kevin Jon Williams Methods and kits for reducing the susceptibility of lipoprotein particles to atherogenic aggregation induced by arterial-wall enzymes
US11541005B2 (en) * 2017-02-08 2023-01-03 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
US11723865B2 (en) 2017-02-08 2023-08-15 New Hope Research Foundation, Inc. Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
CA3087207A1 (en) * 2017-12-28 2019-07-04 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
CN109092262B (zh) * 2018-08-28 2019-07-05 广州达济医学科技有限公司 低密度脂蛋白吸附微球及制备方法和吸附材料
CN111420122A (zh) * 2020-04-30 2020-07-17 山东隽秀生物科技股份有限公司 一种可诱导骨再生的生物膜及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US548961A (en) * 1895-10-29 Machine for removing stems from tobacco-leaves
JPS5348976A (en) * 1976-10-18 1978-05-02 Nippon Zeon Co Ltd Mass transfer apparatus of hollow fiber type
US4247393A (en) * 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
EP0074610B1 (de) * 1981-09-10 1987-05-20 Intermedicat GmbH Verfahren zur selektiven extrakorporalen Präzipitation von Low Density Lipoproteinen aus Vollserum oder Plasma
US4532089A (en) * 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
US4978654A (en) * 1984-04-16 1990-12-18 Board Of Regents, The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US4663167A (en) * 1984-04-16 1987-05-05 The Board Of Regents Of The University Of Texas System Composition and method for treatment of disseminated fungal infections in mammals
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4812314A (en) * 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5252263A (en) * 1986-06-16 1993-10-12 The Liposome Company, Inc. Induction of asymmetry in vesicles
US5219994A (en) * 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5015483A (en) * 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE4018767A1 (de) * 1990-06-12 1991-12-19 Braun Melsungen Ag Wirkstofffreie liposomen zur behandlung von atherosklerose
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
US5250060A (en) * 1992-06-26 1993-10-05 Carbo Paul L Angioplasty apparatus
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5622715A (en) * 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US5489611A (en) * 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
US5858400A (en) * 1995-10-11 1999-01-12 Talaria Therapeutics, Inc. Method of suppressing a rise in LDL concentrations after administration of an agent having small acceptors

Also Published As

Publication number Publication date
CN1228018A (zh) 1999-09-08
US20020064553A1 (en) 2002-05-30
EP0863748A4 (en) 1999-11-03
CA2231547A1 (en) 1997-04-17
US20010009670A1 (en) 2001-07-26
US5948435A (en) 1999-09-07
US5736157A (en) 1998-04-07
WO1997013501A1 (en) 1997-04-17
JP2002515856A (ja) 2002-05-28
US5843474A (en) 1998-12-01
US5858400A (en) 1999-01-12
EA199800279A1 (ru) 1999-04-29
EP0863748A1 (en) 1998-09-16
CN1119145C (zh) 2003-08-27
AU7595696A (en) 1997-04-30
AU759964B2 (en) 2003-05-01
US20020041894A1 (en) 2002-04-11
US6080422A (en) 2000-06-27

Similar Documents

Publication Publication Date Title
MXPA98002791A (es) Composiciones liposomales y metodos para usarlas.
Henriksson et al. Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.
Friis et al. Serum lipids in hyper-and hypothyroidism before and after treatment
Solyom Effect of androgens on serum lipids and lipoproteins
US20080275007A1 (en) Charged phospholipid compositions and methods for their use
Thistle et al. Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man: a dose-response study
Jefcoate et al. Cytochrome P-450 of adrenal mitochondria. In vitro and in vivo changes in spin states.
AU2001278336A1 (en) Charged phospholipid compositions and methods for their use
GB9907037D0 (en) Weight control product and method of treating hyperlipidemia and increasing vigor with said product
Okamoto et al. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones
Leuven Sex steroids and lipoprotein metabolism
Helve et al. Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles
Fugman et al. Lipoprotein lipase-and phospholipase A2-catalyzed hydrolysis of phospholipid vesicles with an encapsulated fluorescent dye effects of apolipoproteins
Loria et al. Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects
Azzarito et al. Long-term therapy with high-dose simvastatin does not affect adrenocortical and gonadal hormones in hypercholesterolemic patients
Krauss Lipids and lipoproteins and effects of hormone replacement
Muntz et al. Phospholipase activity of bovine milk lipoprotein lipase on phospholipid vesicles; Influence of apolipoproteins C-II and C-III
Grundy Hyperlipoproteinemia: metabolic basis and rationale for therapy
Bravo et al. Cardiovascular effects of lovastatin in normotensive and spontaneously hypertensive rats
Ratanasavanh et al. Gamma-glutamyltransferase activity of liver plasma membranes in phenobarbital—Treated rabbits
Moulin et al. High density lipoprotein alterations induced by bezafibrate in healthy male volunteers
SHEPHERD et al. Pharmacological modification of lipoprotein metabolism
Ulloa et al. Increased activity of lecithin: cholesterol acyltransferase during short-term oral estrogen progestin replacement therapy in a group of postmenopausal women
Humble et al. Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors
Chappey-Gillet et al. Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
FA Abandonment or withdrawal